Table 1.
Clinical, serology and pathology features of 7 RDD mimic IgG4-RD patients
| Sequence number | Sex | Age | Organ involvement/symptom | Serology | Pathology | Treatment | Prognosis | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| IgG1 (mg/L) | IgG2 (mg/L) | IgG3 (mg/L) | IgG4 (mg/L) | IgG4 (cells/hpf) | IgG4/IgG (%) | ||||||
| 1 | M | 56 | Spinal pachymeningitis/numbness, walking unstable | 5380 | 5960 | 420 | 4385 | > 50 | 10–30 | Glucocorticoids + cyclophosphamide | Improved |
| 2 | M | 63 | Liver mass, rash, lacrimal gland swollen | 6450 | 7570 | 160 | 6410 | 10–20 | 10 | Glucocorticoids + cyclophosphamide | Improved |
| 3 | M | 61 | Intraspinal mass/skin numbness | 5380 | 5960 | 420 | 5800 | > 50 | 40 | Glucocorticoids + cyclophosphamide/azathioprine | Improved |
| 4 | M | 50 | Pachymeningitis/impaired vision and hearning | 8000 | 2030 | 110 | 292 | 30 | 20 | Glucocorticoids + rituximab (intrathecal injection) | Improved |
| 5 | M | 29 | Pachymeningitis (epilepsia)/subcutanous mass | 8200 | 4230 | 318 | 1360 | > 50 | 40 | Glucocorticoids + cyclophosphamide | Improved |
| 6 | M | 56 | Pancreas and duodenum masses/lymph node enlargement | 12,600 | 12,800 | 763 | 54,100 | > 100 | > 40 | Glucocorticoids | Improved |
| 7 | M | 37 | Sellar region and orbital cavity mass/impaired vision, sinusitis | 8310 | 5880 | 582 | 3510 | > 100 | > 40 | None | Remain the same |
M, male